2月24日,Summit Therapeutics宣布与辉瑞开展临床试验合作,以评估PD-1/VEGF双特异性抗体Ivonescimab(依沃西单抗,康方生物原研)与辉瑞的多种抗体偶联药物(ADCs)联合用于多种实体瘤的疗效和安全性。 根据协议条款,Summit将提供用于拟议研究的Ivonescimab,辉瑞将负责开展研究的运营工作。这些研究将由Summit和辉瑞共同监督。双方各自保留其产品的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.